Effect of Hybrid Blood Purification Treatment on Secondary Hyperparathyroidism for Maintenance Hemodialysis Patients

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.

This study aims to investigate the effects of hybrid blood purification treatment on secondary hyperparathyroidism for maintenance hemodialysis (HD) patients.

Who Took Part

According to the abstract, 40 patients were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

A total of 40 patients were randomly divided into 2 groups: HD combined with hemoperfusion (HD + HP) group (n = 20) and HD group (n = 20).

Changes in intact parathyroid hormone (iPTH) in these 2 groups were compared before and after treatment, and iPTH levels in the HD + HP group were monitored before and after treatment.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

What Was Measured

PubMed files the paper under topics including Cystatin C, Hemoperfusion, Hyperparathyroidism, Secondary, Parathyroid Hormone, Renal Dialysis and beta 2-Microglobulin.

The authors tagged it with the keywords Hemodialysis, Intact parathyroid hormone, Secondary hyperparathyroidism and Treatment cycle.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in 40 patients in people with hyperparathyroidism.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Blood purification), a journal based in Switzerland.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.